New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2013
06:32 EDTPFE, ACT, JNJ, NVS, TEVA, MYL, GNK, BMY, GSKSome justices seem skeptical about payments to generic drug firms, NY Times says
Several Supreme Court justices seemed skeptical about the practice of brand name pharmaceutical companies paying generic companies to keep their cheaper drugs off the market for a longer time, according to The New York Times. Some of the justices appeared to be interested in issuing a narrow ruling in the case they are hearing regarding the issue that would not create a precedent, the newspaper added. Reference Link
News For PFE;ACT;JNJ;NVS;TEVA;MYL;GNK;BMY;GSK From The Last 14 Days
Check below for free stories on PFE;ACT;JNJ;NVS;TEVA;MYL;GNK;BMY;GSK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
August 7, 2014
11:02 EDTBMYBristol-Myers enters development pact with Leica Biosystem
Subscribe for More Information
10:29 EDTMYLMylan: Noise about inversion is tremendous speculation and that's all it is
Subscribe for More Information
10:23 EDTMYLMylan sees FY14 CapEx $350M-$400M
Subscribe for More Information
10:20 EDTMYLMylan sees FY14 adjusted EBITDA $2.2B-$2.4B
Subscribe for More Information
10:20 EDTMYL, TEVAMylan says litigation ins ongoing in India regarding Teva
Mylan (MYL) said that it expects Teva's (TEVA) efforts to seek an injunction will "as ineffective as it was in U.S. courts." The company said it will not provide further comment on the matter. Mylan said it will also postpone its 2014 Investor Day due to the ongoing nature of the Abbott (ABT) transaction. It expects its fully realized savings and profit from new products will not be realized till 2015. Comments taken from Q2 earnings conference call.
09:28 EDTACTDepomed may add another pain product to portfolio, says Janney Capital
Subscribe for More Information
08:38 EDTNVSEnanta's HCV NS5A inhibitor EDP-239 advances into combination studies
Subscribe for More Information
08:12 EDTPFEPfizer says EMA accpets application seeking new indication for Prevenar 13
Subscribe for More Information
06:42 EDTMYLObama to look to limit inversion deals, Politico says
Subscribe for More Information
06:37 EDTMYLMylan narrows FY14 adjusted EPS view to $3.25-$3.45 from $3.25-$3.60
Consensus $3.37. Narrows FY14 revenue guidance to $7.8B-$8B from $7.8B-$8.2B, consensus $7.77B.
06:36 EDTMYLMylan sees Q3 EPS 90c-95c, consensus $1.03
Subscribe for More Information
06:34 EDTMYLMylan reports Q2 adjusted EPS 69c, consensus 70c
Reports Q2 revenue $1.84B, consensus $1.88B.
August 6, 2014
15:49 EDTMYLNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Duke Energy (DUK), consensus 98c; Intercontinental Exchange (ICE), consensus $2.02; Mylan (MYL), consensus 70c; Scripps Networks (SNI), consensus $1.13; Brinker International (EAT), consensus 87; AES Corporation (AES), consensus 28c; NRG Energy (NRG), consensus 15c; Harman International (HAR), consensus $1.21; Windstream Holdings (WIN), consensus 8c; Teradata (TDC), consensus 65c; Markel (MKL), consensus $5.79; OGE Energy (OGE), consensus 51c; SunEdison (SUNE), consensus (28c); Royal Gold (RGLD), consensus 29c; Sabre (SABR), consensus 18c; Broadridge (BR), consensus $1.16; Huntington Ingalls (HII), consensus $1.81; AMC Networks (AMCX), consensus 85c; Laredo Petroleum (LPI), consensus 18c; HSN (HSNI), 77c; Wendy's (WEN), consensus 10c; Orbitz Worldwide (OWW), consensus 15c.
14:52 EDTACTActavis weakness on tax related concerns overdone, says Sterne Agee
Subscribe for More Information
12:10 EDTPFEPfizer settles multi-state complaint on improper promotion of Rapamune
Attorney General Eric T. Schneiderman announced that he, along with 40 other state Attorneys General and the District of Columbia, reached a $35M settlement with Pfizer arising from alleged improper marketing and promotion of the immunosuppressive drug Rapamune. New York’s share of the settlement is over $1.7M. Pfizer, as parent of Wyeth Pharmaceuticals, agrees to be bound by the judgment and to resolve allegations that Wyeth unlawfully promoted Rapamune. Attorney General Schneiderman’s office served on the Executive Committee of this multi-state investigation. Reference Link
07:31 EDTACTActavis price target raised to $254 from $237 at UBS
Subscribe for More Information
07:02 EDTGSKSynta Pharmaceuticals names Anne Whitaker as CEO, effective September 2
Subscribe for More Information
06:41 EDTMYLObama administration may restrict inversion tax benefits, NY Times says
Subscribe for More Information
06:23 EDTPFEMitsubishi UFJ to hold a conference
Subscribe for More Information
06:21 EDTJNJ, PFEPiper Jaffray to hold a summit
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use